Sage Therapeutics Inc. | Ownership
Companies that own Sage Therapeutics Inc.
T. Rowe Price Associates, Inc.
7,632,429
16.36%
476,305
0.17%
06/30/2018
Fidelity Management & Research Co.
6,935,978
14.86%
103,287
0.12%
06/30/2018
The Vanguard Group, Inc.
3,795,902
8.14%
116,916
0.02%
06/30/2018
BlackRock Fund Advisors
2,280,858
4.88%
-762,596
0.02%
06/30/2018
Wellington Management Co. LLP
1,981,504
4.25%
-287,018
0.06%
06/30/2018
OppenheimerFunds, Inc.
1,598,167
3.43%
34,389
0.15%
06/30/2018
Bellevue Asset Management AG
1,083,473
2.31%
68,584
2.57%
06/30/2018
SSgA Funds Management, Inc.
997,406
2.14%
-235,772
0.01%
06/30/2018
Palo Alto Investors LP
832,536
1.78%
14,205
5.26%
06/30/2018
BNY Mellon Asset Management North America Corp.
817,603
1.75%
79,149
0.07%
06/30/2018
| Address |
215 First Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.sagerx.com |
| Updated |
07/08/2019 |
| SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |
